You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186.HK)向ESTEVE授予新藥利斯的明多天貼劑於西班牙的獨家商業化權利
格隆匯 09-08 21:34

格隆匯9月8日丨綠葉製藥(02186.HK)公吿,集團全資附屬公司Luye Pharma Switzerland AG(綠葉瑞士)與ESTEVE Pharmaceuticals S.A.訂立協定,據此,ESTEVE獲得新藥利斯的明多日透皮貼劑在西班牙的獨家商業化權利。

根據該協定,ESTEVE獲得在西班牙商業化利斯的明多天貼劑的獨家權利。董事會相信,ESTEVE作為一家擁有豐富中樞神經治療領域經驗和強大商業運營體系的知名製藥公司,將擴大利斯的明多天貼劑的可及性,以滿足該地區患者未滿足的需求。

阿爾茨海默病仍然是全球範圍的一大健康難題,患者數量不斷增長。利斯的明是治療阿爾茨海默病相關痴呆症的一線藥物,目前已在全球上市。

據悉,利斯的明多天貼劑是一週兩次的利斯的明創新貼片劑型,用於治療與阿爾茨海默病相關的輕中度痴呆症。該產品由集團專有的透皮釋藥技術平台開發,是集團在中樞神經治療領域的核心產品之一。

利斯的明是一類稱為膽礆酯酶抑制劑的藥物。該類藥物可以通過增加大腦中某些天然物質的數量,並放大神經細胞之間的溝通通道來改善記憶和思維等認知功能,而神經細胞在輕度至中度阿爾茨海默病患者中的活性較弱。目前該藥以片劑和貼片的形式提供。

除歐洲市場外,利斯的明多天貼劑也將會在全球其他的主要市場註冊,包括中國、日本和其他國家或地區。於2020年9月,該產品已獲得中國國家藥品監督管理局藥品審評中心批准進入臨牀試驗。於2021年2月,利斯的明多天貼劑在日本的獨家開發及商業化權利被授予給Towa Pharmaceutical Co.,Ltd.並即將開始III期臨牀試驗。

ESTEVE(www.esteve.com)是一家總部位於巴賽隆納的國際製藥公司。它的使命是推進創新以改善人們的生活,自1929年成立以來,它一直專注於為尚未涵蓋的醫療需求提供解決方案。ESTEVE在歐洲和美國均有重要業務。該公司通過子公司在美國運營,其在西班牙、墨西哥和中國的生產設施致力於開發和製造活性藥物成分,並在德國設有一家制藥廠。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account